Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 7/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.43 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.41 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.41 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.41 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13812239 | 0.85 | LMNA (0.41) | LMNAKCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL9564871 | 0.79 | HDAC1 (0.54) | EGFRLMNASMN1; SMN2KCNQ3KCNQ2 | |
| SCHEMBL4151526 | 0.73 | HPGD (0.51) | SLC22A12MAPK14PLA2G7 | |
| SCHEMBL11237461 | 0.72 | KMT2A (0.55) | LMNASMN1; SMN2CYP3A4 | |
| SCHEMBL4157702 | 0.67 | SLC22A12 (0.44) | SLC22A12SCN9ACYP3A4 | |
| SCHEMBL28288017 | 0.67 | KDM4E (0.56) | SLC22A12PLA2G7SCN9A | |
| SCHEMBL2534052 | 0.67 | VNN1 (0.54) | LMNAL3MBTL1KCNQ3KCNQ2KCNE1 | |
| SCHEMBL3142244 | 0.67 | HDAC1 (0.55) | LMNASMN1; SMN2L3MBTL1KCNQ3KCNQ2 | |
| SCHEMBL4152465 | 0.66 | VNN1 (0.53) | L3MBTL1KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL12412741 | 0.66 | GRM5 (0.54) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149452-A1 | XANTHINE OXIDASE INHIBITOR | NIPPON CHEMIPHAR CO., LTD. (JP) | 2009-06-11 | — | — | US | disclosed |
| EP-1911760-A1 | XANTHINE OXIDASE INHIBITOR | Nippon Chemiphar Co., Ltd. (JP) | 2008-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149452-A1 | XANTHINE OXIDASE INHIBITOR | XDH, PNPO, CBR1 | EGFR 4154/4885SLC22A12 1556/4885MAPK14 2911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.